Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
Boehringer Ingelheim
US Army
Merck
QuintilesIMS
Moodys
Cerilliant
Mallinckrodt

Generated: June 23, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,339,489

« Back to Dashboard

Which drugs does patent 9,339,489 protect, and when does it expire?

Patent 9,339,489 protects SPRITAM and is included in one NDA.

This patent has twelve patent family members in eight countries.
Summary for Patent: 9,339,489
Title:Rapid disperse dosage form containing levetiracetam
Abstract: A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.
Inventor(s): Jacob; Jules (Yardley, PA), Coyle; Norman (Fort Washington, PA), West; Thomas G (Lawrenceville, NJ), Monkhouse; Donald C. (Radnor, PA), Surprenant; Henry L. (Phoenixville, PA), Jain; Nemichand B. (Princeton Junction, NJ)
Assignee: Aprecia Pharmaceuticals Company (Langhorne, PA)
Application Number:14/277,901
Patent Claim Types:
see list of patent claims

Drugs Protected by US Patent 9,339,489

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-004 Jul 31, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LEVETIRACETAM ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-001 Jul 31, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LEVETIRACETAM ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-002 Jul 31, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LEVETIRACETAM ➤ Sign Up
Aprecia Pharms SPRITAM levetiracetam TABLET, FOR SUSPENSION;ORAL 207958-003 Jul 31, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y METHOD OF ADMINISTERING LEVETIRACETAM ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,339,489

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,669,009 Rapid disperse dosage form containing levetiracetam ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
Julphar
Deloitte
Chinese Patent Office
Cipla
Farmers Insurance
US Department of Justice
Citi
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.